Results 1 to 10 of about 659,528 (297)

Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. [PDF]

MMWR Recomm Rep, 2023
Summary This report compiles and summarizes all published recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP) for use of pneumococcal vaccines in adults aged ≥19 years in the United States. This report also includes updated and
Kobayashi M, Pilishvili T, Farrar JL, Leidner AJ, Gierke R, Prasad N, Moro P, Campos-Outcalt D, Morgan RL, Long SS, Poehling KA, Cohen AL.   +11 more
europepmc   +2 more sources

Cost-effectiveness analysis of a maternal pneumococcal vaccine in low-income, high-burden settings such as Sierra Leone [PDF]

PLOS Global Public Health, 2023
Maternal pneumococcal vaccines have been proposed as a method of protecting infants in the first few months of life. In this paper, we use results from a dynamic transmission model to assess the cost-effectiveness of a maternal pneumococcal ...
Gizem M. Bilgin, Syarifah Liza Munira, Kamalini Lokuge, Kathryn Glass   +3 more
doaj   +2 more sources

A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host [PDF]

Nature Communications, 2019
Chemical synthesis of conjugate vaccines, consisting of a polysaccharide linked to a protein, can be technically challenging, and in vivo bacterial conjugations (bioconjugations) have emerged as manufacturing alternatives.
Chavez, Sthefany M., Feldman, Mario F., Huynh, Jeremy P., Kinsella, Rachel L., Mayer, Anne E., Stallings, Christina L.   +5 more
core   +3 more sources

Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development [PDF]

Vaccines
Pneumococcal vaccines are a cornerstone for the prevention of pneumococcal diseases, reducing morbidity and mortality in children and adults worldwide.
Kristen Feemster, William P. Hausdorff, Natalie Banniettis, Heather Platt, Priscilla Velentgas, Alejandra Esteves-Jaramillo, Robert L. Burton, Moon H. Nahm, Ulrike K. Buchwald   +8 more
doaj   +2 more sources

Multi-serotype pneumococcal nasopharyngeal carriage prevalence in vaccine naïve Nepalese children, assessed using molecular serotyping. [PDF]

, 2015
Invasive pneumococcal disease is one of the major causes of death in young children in resource poor countries. Nasopharyngeal carriage studies provide insight into the local prevalence of circulating pneumococcal serotypes.
Adhikari, N, Gould, KA, Gurung, M, Hinds, J, Kandasamy, R, Kelly, DF, Murdoch, DR, Ndimah, S, Pollard, AJ, Shrestha, S, Thapa, A, Thorson, S, Waldron, DE   +12 more
core   +25 more sources

Effectiveness of pneumococcal vaccine [PDF]

The Lancet, 1998
Åke Örtqvist, Jonas Hedlund, Mats Kalin   +2 more
openalex   +4 more sources

Pneumococcal vaccine [PDF]

Journal of Medical Microbiology, 1996
Streptococcus pneumoniae, commonly termed the pneumococcus, is a major pediatric pathogen both in developed and developing countries. Despite the availability of multiple antimicrobials to which this organism is susceptible, it continues to cause significant morbidity and mortality. Recognition of the limitations of antimicrobial therapy in controlling
G, Peter, J O, Klein
openaire   +4 more sources

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

MMWR. Morbidity and mortality weekly report, 2022
In 2021, 20-valent pneumococcal conjugate vaccine (PCV) (PCV20) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.) and 15-valent PCV (PCV15) (Merck Sharp & Dohme Corp.) were licensed by the Food and Drug Administration for adults aged ≥18 years ...
Miwako Kobayashi, Jennifer L. Farrar, R. Gierke, Amadea Britton, L. Childs, A. Leidner, D. Campos-Outcalt, Rebecca L Morgan, Sarah S. Long, H. Talbot, K. Poehling, T. Pilishvili   +11 more
semanticscholar   +1 more source

Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

MMWR. Morbidity and mortality weekly report, 2022
The 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer, Inc]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Merck Sharp & Dohme LLC]) have been recommended for U.S.
Miwako Kobayashi, Jennifer L. Farrar, R. Gierke, A. Leidner, D. Campos-Outcalt, Rebecca L Morgan, S. Long, K. Poehling, A. Cohen, K. Poehling, S. Long, J. Kelman, Lucia Lee, Tina Mongeau, T. Weiser, Uzo Chukwuma, Kristina Lu, M. Makhene, Lynn Fisher, Mark Sawyer, Jason Goldman, D. Nace, Emily Messerli, Elissa Abrams, Aleksandra K. Wierzbowski, Carol Baker, James McAuley, W. Schaffner, Virginia Cane, D. Campos-Outcalt, M. Farley, K. Klugman, Rebecca L Morgan, A. Reingold, L. Rubin, C. Whitney, R. Zimmerman, Emma K. Accorsi, Alison P. Albert, Shriya Bhatnagar, L. Childs, M. Fischer, R. Gorwitz, Angela J. Jiles, Heidi L Moline, P. Moro, Chukwuebuka Nsofor, N. Prasad, H. Walker, Jacquline Risalvato, S. Schillie   +50 more
semanticscholar   +1 more source

Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults

Microorganisms, 2021
Pneumococcal disease is one of the most common and severe vaccine-preventable diseases (VPDs). Despite the advances in antimicrobial treatment, pneumococcal disease still remains a global burden and exhibits a high mortality rate among people of all ages
Nobuhiro Asai, Hiroshige Mikamo
doaj   +1 more source